AbbVie’s stock took a significant hit after two Phase 2 trials investigating emraclidine, a potential schizophrenia treatment, failed to meet their primary endpoint. Despite this setback, analysts remain positive on AbbVie’s overall pipeline, pointing to the promising Cerevel acquisition and other treatments in development. This news could also impact the schizophrenia drug market, with analysts questioning the effectiveness of selective muscarinic targeting and highlighting the potential advantages of Bristol Myers Squibb’s Cobenfy.
